Significance Of Gene Mutation And Protein Expression Of EGFR,KRAS And BRAF In Ovarian Serous Tumors

Objective: In this study,we detected the mutations and proteins of epidermal growth factor receptor(EGFR),murine sarcoma virus oncogene(KRAS)and murine sarcoma filter toxin carcinogen B(BRAF)gene in ovarian serous tumors.The expression situation,preliminary exploration of its role in the occurrence and development of serous ovarian tumors.Methods: The patients with serous ovarian tumors diagnosed in the Department of Pathology,Affiliated Hospital of Zunyi Medical University from January 2008 to December 2019 were collected.According to the diagnostic criteria for ovarian serous tumors in the 2014 World Health Organization(WHO)classification of female reproductive organ tumors: 10 cases of ovarian serous cystadenoma(OSA)and 40 cases of ovarian serous borderline tumor(OSBT)19 cases of low-grade serous carcinoma of the ovary(LGOSC).Using NGS sequencing to detect EGFR,KRAS and BRAF gene mutations for qualitative analysis.Immunohistochemical Envision method was used to detect the expression of EGFR,KRAS and BRAF proteins,and Image-ProPlus software was used to calculate the protein expression intensity.The data was statistically analyzed using SPSS 23.0 software,with ?=0.05 as the test level,and P<0.05 indicated that the difference was statistically significant.Results:1.Expression and intensity of EGFR,KRAS,BRAF protein in OSA,OSBT,LGOSCThe positive expression rates of EGFR in OSA,OSBT,and LGOSC were 30.0%,47.5%,and 89.5%,respectively,and the three groups were statistically significant(P<0.05).LGOSC group was different from OSBT group and OSA group,respectively,Statistical significance(P<0.05),there was no statistically significant difference between OSBT group and OSA group.The MOD values of EGFR in the OSA,OSBT,and LGOSC groups were 0.0366,0.1150,and 0.1774,respectively,and there were statistically significantdifferences between groups and pairwise comparisons(P<0.05).The positive expression rates of KRAS in OSA,OSBT,and LGOSC tissues were 20%,40%,and 78.9%,respectively,and the three groups were statistically significant(P<0.05),LGOSC group was statistically different from OSBT and OSA groups,respectively,(P<0.05),OSBT group and OSA group had no statistical significance(P>0.05).The MOD values of KRAS in the OSA,OSBT,and LGOSC groups were 0.0356,0.1170,and 0.1358,respectively,and the three groups were statistically significant(P<0.05),among them,the OSA group was statistically significant compared with the OSBT and LGOSC groups(P<0.05),the OSBT group and LGOSC group had no statistical significance(P>0.05).The positive expression rates of BRAF in OSA,OSBT,and LGOSC tissues were 10.0%,80.0%,and 47.4%,respectively,between groups and two pairs the comparisons were statistically significant(P<0.05).The MOD values in OSA,OSBT,LGOSC group were0.0269,0.1390,0.1033,between groups and two pairs the comparisons were statistically significant(P<0.05).2.The relationship between the protein expression,gene mutation of EGFR,KRAS and BRAF in LGOSC and the clinicopathological characteristics of patientsThe expression intensity of EGFR and KRAS protein were closely related to the International Federation of Gynecology and Obstetrics(FIGO)stage(P<0.05),and they were not significantly different from age,lymph node metastasis and recurrence(P>0.05).The intensity of BRAF protein table is closely related to FIGO and lymph node metastasis(P<0.05).The MOD value of patients with lymph node metastasis is higher than that of patients without lymph node metastasis(P<0.05),and there is no significant difference with age and recurrence(P>0.05).KRAS,BRAF gene mutation rate and clinicopathological characteristics were not statistically significant(P>0.05).3.Correlation analysis of EGFR,KRAS and BRAF protein expression intensity in LGOSCThe correlation coefficient between EGFR and KRAS is 0.467(P<0.05),the correlation coefficient between EGFR and BRAF is-0.335(P>0.05),and the correlation coefficient between BRAF and KRAS is-0.066(P>0.05),that is,there is a related positive relationship between EGFR and KRAS in LGOSC group.4.Kappa consistency test of NGS and IHC two detection methodsKRAS gene,?=0.600(P<0.05)indicates that the detection results of the two methods are consistent,and the consistency is good.BRAF gene;?=1.000,(P<0.05)indicates that the detection results of the two methods are consistent,and the consistency is good.5.EGFR,KRAF and BRAF proteins and mutations and the prognosis of LGOSCThe positive expression of EGFR and KRAS protein had no significant relationship with the patient's overall survival time(P>0.05),and the BRAF mutation was statistically significant(P<0.05).Mutations of EGFR,KRAS and BRAF genes were not statistically significant in the overall survival time of patients in LGOSC group(P>0.05).Conclusion:1.EGFR,KRAS and BRAF protein expression may participate in the process of LGOSC development,and may help the diagnosis and differential diagnosis of OSBT and LGOSC.2.Both EGFR and KRAS protein expression intensity are related to FIGO stage,which may be of certain value in evaluating the prognosis of patients.IHC detection of KRAS protein may be used as a surrogate marker for KRAS mutations.3.The expression of BRAF protein is related to FIGO stage and lymph node metastasis,and the overall survival time of patients with positive expression is longer than that of patients with negative expression.BRAF protein may be related to prognosis.